Onsolis News and Research

RSS
BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BDSI announces FDA approval of sNDA for new formulation of ONSOLIS (fentanyl buccal soluble film) CII

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences updates on Clonidine Topical Gel Phase 3 trial for PDN treatment

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

Meda reaches agreement with Valeant to terminate joint ventures

Meda reaches agreement with Valeant to terminate joint ventures

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International submits BUNAVAIL NDA to FDA

BioDelivery Sciences International submits BUNAVAIL NDA to FDA

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

Enrollment complete in BDSI's pivotal pharmacokinetic study of BNX for opioid dependence

BDSI announces postponement of ONSOLIS U.S. relaunch

BDSI announces postponement of ONSOLIS U.S. relaunch

USPTO rejects MonoSol's patent infringement claims against BDSI

USPTO rejects MonoSol's patent infringement claims against BDSI

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Single shared REMS for TIRF products receives FDA approval

Single shared REMS for TIRF products receives FDA approval

Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

Positive results from BDSI's BEMA Buprenorphine/Naloxone formulation Phase 1 study on opioid dependence

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BDSI's BEMA drug delivery technology receives Canada patent

BDSI's BEMA drug delivery technology receives Canada patent

BDSI prices $15 million private placement

BDSI prices $15 million private placement

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA